Please assess the completion status of the following clinical trial:

Trial Title: Influence on Erythropoetin-level by Xenon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects~* Age: \> 18 years~* legally competent to sign~* without any known medical condition or medication prescribed at the University Hospital RWTH Aachen, Germany~* Persons that are able and willing to understand and follow the instructions of the study personnel~* Signed informed consent~Exclusion Criteria:~* Smoker, alcoholic or person who regularly consumes drugs or medication~* Persons with a medical condition that is contraindicated with the planned treatment~* Known hypersensitivity against xenon~* Persons not legally competent to sign~* Simultaneous participation at any other trial~* Blood-loss due to trauma during the period of the study or 2 months previous~* Blood donation during the period of the study or 2 months previous

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 10min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 10min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 30min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 30min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 45min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 45min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 90min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 90min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 10min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 10 minutes of air medicinalis (with 75 % FiO2)
- 10min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 10 minutes of air medicinalis inhalation (with 60 % FiO2)
- 30min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 30 minutes of air medicinalis inhalation (with 75 % FiO2)
- 30min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 30 minutes of air medicinalis inhalation (with 60 % FiO2)
- 45min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 45 minutes of air medicinalis inhalation (with 75 % FiO2)
- 45min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 45 minutes of air medicinalis inhalation (with 60 % FiO2)
- 90min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 90 minutes of air medicinalis inhalation (with 75 % FiO2)
- 90min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 90 minutes of air medicinalis inhalation (with 60 % FiO2)

Based on this trial design, predict the completion outcome and termination type (if applicable).